Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

Fig. 6

Genes from the BTRH signature predicts trastuzumab resistance in HER2+ patients. The role of individual genes from BTSH and BTRH signatures predicting trastuzumab and lapatinib response was evaluated. Correlation of gene expression and dual HER2 blockade response was assessed by PAM50 at day 14 (A), pathological complete response at surgery (B) and residual cancer burden score at surgery (C). Box plots show expression of indicated genes in each patient sample. Data is represented as the mean of normalized gene expression. Each sample is indicated by +. RCB: residual cancer burden

Back to article page